Tags » Novartis » Page 3

SLE Market Likely To Reach A Valuation Of Around USD 3.08 Billion By 2025 | Key Industry participants GlaxoSmithKline, Roche

The global Systemic Lupus Erythematosus Market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. 534 more words


Novartis melanoma combination wins key thumbs-up from cost watchdog NICE after Opdivo shut out

Just one week after Bristol-Myers Squibb failed to gain a recommendation for coverage in the U.K. for Opdivo in adjuvant melanoma, Novartis has one-upped its rival with an approval in the same setting. 79 more words

Latest News

Shots, shots, shots, shots, shots💉💉

Heyyy y’all! I’ve decided that I’m going to attempt to put this little “journey” into a blog that way people who want to read it, can and those who don’t, won’t receive the notifications and can mosey on their way! 2,332 more words

Italian CDMO buys India API plant that supplies Novartis

CDMO Olon is continuing its expansion binge with a deal to buy an API plant in India that supplies ingredients to Novartis.

The Italian generic drug and API maker said Tuesday that it is buying an API manufacturing facility in Mahad, India, that supplies ingredients to Sandoz, the generics division of Novartis. 134 more words

Latest News

Alive and kicking - current location: Tirolian Mountains

Shame on me – dead silence for over 9 months.. The good news: I’ve been everything but silent in real life! The bad news: way too much has happened to give a proper update. 888 more words


"Dying to Survive" and Pharmaceutical IP Reform in China

Last week while in Beijing, I finally had the opportunity to see “Dying to Survive” (Chinese title: “我不是药神”), the hit Chinese movie which concerns the problem of high priced cancer medicines that were not available through insurance on the Chinese market and had also been subject to patent validity and infringement disputes.  467 more words

China IPR

Drug Giant Novartis Is Temporarily Backing Off Price Increases Following Trump Pressure

President Trump on Thursday praised drug giant Novartis for temporarily postponing drug price hikes less than a week after Pfizer made a similar decision. But it’s unclear how much Novartis’ move will actually benefit consumers and patients. 192 more words